Cytokinetics, Incorporated Income Statement 2025-1998 | CYTK

Brief overview of revenue and earnings at Cytokinetics, Incorporated

The conclusions below are based on five years of reported results. Cytokinetics, Incorporated reported revenue of $55.8 million in 2020 and $88 million by 2025. The five-year change reached +57.7%, while CAGR stood at 9.5%. The direction is positive, but the growth rate is not particularly high.

The operating result measured by EBITDA moved from −92.1 million dollars to −602 million dollars, or −553.7%. Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from −165% to −683.9%. Operating return per unit of revenue declined.

The final result was −$127 million initially and −$785 million in the final year. The period ended with a larger loss than it began with.

The market value of the business moved from 1.3 million dollars to 7.5 million dollars, or +462.9%. The market value rose well beyond the pace of financial improvement.

Financial takeaway

The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on a larger revenue base. The weaker side of the profile includes declining net profitability, a declining EBITDA margin and a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.